Valuation: Gabather AB

Market Cap 12.21M 1.24M 1.11M 1.02M 928K 1.73M 118M 1.77M 4.9M 62.08M 4.66M 4.57M 196M P/E 2024
-1.07x
P/E 2025 -1.13x
Enterprise Value 9.07M 923K 827K 760K 689K 1.29M 87.63M 1.31M 3.64M 46.1M 3.46M 3.39M 145M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
91.04%
Yield 2024 *
-
Yield 2025 -
1 day+9.89%
1 week-4.76%
Current month-28.57%
1 month-28.57%
3 months-37.11%
6 months-50.98%
Current year-27.01%
1 week 0.02
Extreme 0.0182
0.02
1 month 0.02
Extreme 0.0182
0.03
Current year 0.02
Extreme 0.0182
0.1
1 year 0.02
Extreme 0.0182
0.1
3 years 0.02
Extreme 0.0182
4.2
5 years 0.02
Extreme 0.0182
6.45
10 years 0.02
Extreme 0.0182
53.2
Manager TitleAgeSince
Chief Executive Officer - 01/10/2018
Chief Operating Officer - 01/01/2018
Chief Tech/Sci/R&D Officer - 01/01/2018
Director TitleAgeSince
Director/Board Member - 01/09/2014
Director/Board Member 60 03/11/2014
Chairman - 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
+9.89%-4.76%-57.08%-99.12% 1.24M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +1.29%+6.31%+37.37%+175.78% 39.43B
Weighted average by Cap. +0.18%+5.44%+48.50%+186.13%

Financials

2024 2025
Net sales - -
Net income -7.75M -789K -707K -650K -589K -1.1M -74.93M -1.12M -3.11M -39.42M -2.96M -2.9M -124M -4.65M -474K -424K -390K -353K -661K -44.96M -673K -1.87M -23.65M -1.78M -1.74M -74.59M
Net Debt -878K -89.37K -80.04K -73.63K -66.71K -125K -8.49M -127K -352K -4.46M -335K -328K -14.08M -3.14M -320K -287K -264K -239K -446K -30.38M -455K -1.26M -15.98M -1.2M -1.18M -50.39M
Projected Income Statement - Annual - Gabather AB
Logo Gabather AB
Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.
Employees
2
Date Price Change Volume
30/10/26 SEK 0.0200 +9.89% 11,584,259
29/10/26 SEK 0.0182 -7.14% 813,169
28/10/26 SEK 0.0196 -1.01% 3,931,480
27/10/26 SEK 0.0198 -2.94% 467,271
26/10/26 SEK 0.0204 -2.86% 3,020,977
  1. Stock Market
  2. Stocks
  3. GABA Stock